Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma

Craig Moskowitz • 5 Dec 2014
ASH 2014
Hodgkin Lymphoma Antibodies Brentuximab vedotin
AETHERA

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) presents results from the phase III AETHERA trial, which evaluated the safety and efficacy of brentuximab vedotin in preventing post-autologous stem cell transplant disease recurrence in Hodgkin lymphoma patients.

More from Craig Moskowitz

5:56
Phase Ib shows pembrolizumab elicits complete or partial remission in Hodgkin lymphoma
Craig Moskowitz • 9 Apr 2015
23:35
ASH 2014: Ask the experts Q&A session 1
Catherine Bollard et al. • 6 Dec 2014

Related Videos

2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:50
Results of the EuroNet-PHL-C1 trial: omission of radiotherapy in children and adolescents with cHL
Christine Mauz-Körholz • 8 Dec 2023
1:17
KEYNOTE-667: pembrolizumab plus COPDAC-28 for high-risk cHL with slow early response to OEPA
Christine Mauz-Körholz • 8 Dec 2023
0:52
Managing late effects of treatment in pediatric patients with Hodgkin lymphoma
Christine Mauz-Körholz • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals